retatrutide phase 2 trial type 2 diabetes weight loss is investigational and is not FDA approved. In TRANSCEND-T2D-1, investigators randomized 537 adults with inadequately controlled by diet and exercise in a 40-week, double-blind, placebo-controlled 3 ๐ A triple-action once-weekly injection
Pay in 4 interest-free payments of $7.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 2 - Aug 7
























